SCHEMBL29875445

SCHEMBL29875445

NC(=NO)c1ncco1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24641068 1.00
SCHEMBL17926752 0.75
SCHEMBL518554 0.73
SCHEMBL1459930 0.73
Hydrochloric Acid SCHEMBL28507568 0.71 FAAH (0.43)
Hydrochloric Acid SCHEMBL6207350 0.71
SCHEMBL5610307 0.70 FAAH (0.42)
SCHEMBL1231949 0.67 FAAH (0.47)
SCHEMBL28892029 0.67 FAAH (0.39)
SCHEMBL11130354 0.67 FAAH (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117479934-A HIPK2 inhibitors for the treatment of renal fibrosis 西奈山伊坎医学院 2024-01-30 CN disclosed
EP-4291183-A1 OXADIAZOLYL DIHYDROPYRANO[2,3-B]PYRIDINE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS Icahn School of Medicine at Mount Sinai (US) 2023-12-20 EP disclosed
WO-2022173795-A1 OXADIAZOLYL DIHYDROPYRANO[2,3-b]PYRIDINE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2022-08-18 WO disclosed